52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Allogene Therapeutics Reports Second Quarter 2019 Financial Results
Allogene Therapeutics Reports Q1 Loss Per Share Of $0.32
Allogene Therapeutics Reports Q4, FY2018 Results
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.
Biotechnology & Drugs
210 E Grand Ave
Arie S. Belldegrun
Executive Chairman of the Board, Co-Founder
President, Chief Executive Officer, Co-Founder, Director
Joshua A. Kazam
Eric T. Schmidt
Chief Financial Officer
Chief Technical Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were on pace for their fifth day of losses on Friday, after weak U.S. jobs data in February added...
Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions.
Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in the U.S. markets spurred by investors fretting over an economic slowdown.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.